++ IVAX´S -BIG NEWS- ++ - 500 Beiträge pro Seite
eröffnet am 15.09.00 21:18:14 von
neuester Beitrag 21.09.00 23:55:11 von
neuester Beitrag 21.09.00 23:55:11 von
Beiträge: 3
ID: 244.235
ID: 244.235
Aufrufe heute: 0
Gesamt: 414
Gesamt: 414
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
08.05.24, 11:56 | 228 | |
gestern 18:21 | 196 | |
heute 03:11 | 196 | |
17.05.24, 19:20 | 173 | |
heute 03:06 | 159 | |
heute 00:02 | 152 | |
heute 02:00 | 139 | |
gestern 22:33 | 117 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.704,42 | -0,18 | 186 | |||
2. | 4. | 6,5320 | -2,74 | 81 | |||
3. | 14. | 22,210 | -19,73 | 73 | |||
4. | 18. | 31,61 | +7,14 | 69 | |||
5. | 6. | 10,700 | +1,71 | 66 | |||
6. | 10. | 16,750 | +4,69 | 47 | |||
7. | 5. | 177,46 | +1,50 | 47 | |||
8. | 3. | 4,4000 | -5,17 | 42 |
gerade reingekommen
FDA approves IVAX` generic form of Bristol cancer drug Taxol
NEW YORK, Sept 15 (Reuters) - IVAX Corp. said on
Friday it has received approval from U.S. regulators to sell a
generic form of Taxol, a victory in the company`s heated battle
to sell a copycat version of Bristol-Myers` blockbuster
treatment for ovarian and breast cancer.
IVAX has been fighting New York drug giant Bristol-Myers
for two years to sell its version of Taxol, whose
chemical name is paclitaxel. It will be the first generic form
of Taxol on the U.S. market, which means that no other generic
drugmaker can sell generic paclitaxel for 180 days.
Taxol, which Bristol-Myers launched in 1993, had been
expected by Wall Street analysts to have U.S. sales in 2000 of
over $1 billion, thanks to the drug giant`s longtime marketing
exclusivity on the treatment. But Taxol will now have to
contend with the IVAX version of the drug, which some analysts
have predicted could generate sales of $100 million or more in
its first full year on the U.S. market.
Miami-based IVAX has accused Bristol-Myers of attempting to
delay introduction of its cheaper product. "Anyone who has
followed IVAX` efforts to bring its generic version of Taxol to
market in the United States knows IVAX has had to overcome a
succession of disruptive and delaying tactics," said Neil
Flanzraich, vice chairman and president of IVAX.
"We strongly believe the system must be changed to
eliminate opportunities for abuse by those seeking to prevent
or delay generic competition, and we will say more about that
in the future," he added.
FDA approves IVAX` generic form of Bristol cancer drug Taxol
NEW YORK, Sept 15 (Reuters) - IVAX Corp. said on
Friday it has received approval from U.S. regulators to sell a
generic form of Taxol, a victory in the company`s heated battle
to sell a copycat version of Bristol-Myers` blockbuster
treatment for ovarian and breast cancer.
IVAX has been fighting New York drug giant Bristol-Myers
for two years to sell its version of Taxol, whose
chemical name is paclitaxel. It will be the first generic form
of Taxol on the U.S. market, which means that no other generic
drugmaker can sell generic paclitaxel for 180 days.
Taxol, which Bristol-Myers launched in 1993, had been
expected by Wall Street analysts to have U.S. sales in 2000 of
over $1 billion, thanks to the drug giant`s longtime marketing
exclusivity on the treatment. But Taxol will now have to
contend with the IVAX version of the drug, which some analysts
have predicted could generate sales of $100 million or more in
its first full year on the U.S. market.
Miami-based IVAX has accused Bristol-Myers of attempting to
delay introduction of its cheaper product. "Anyone who has
followed IVAX` efforts to bring its generic version of Taxol to
market in the United States knows IVAX has had to overcome a
succession of disruptive and delaying tactics," said Neil
Flanzraich, vice chairman and president of IVAX.
"We strongly believe the system must be changed to
eliminate opportunities for abuse by those seeking to prevent
or delay generic competition, and we will say more about that
in the future," he added.
Hat einer News von Ivax ????
über 6 % bei den Amis im Plus.
Oder kommt das, weil Global Biotech Ivax wieder empfohlen hat ?
über 6 % bei den Amis im Plus.
Oder kommt das, weil Global Biotech Ivax wieder empfohlen hat ?
Numbers of Brokers Recommending (09/18/00)
Strong Buy 6
Moderate Buy 3
Hold 0
Moderate Sell 0
Strong Sell 0
Current Average Recommendation (1.0=Strong Buy, 5.0=Strong Sell): 1.3
Last Weeks Average Recommendation: 1.4
Change In Average Recommendation: 0.1
Sieht doch echt gut aus...
Strong Buy 6
Moderate Buy 3
Hold 0
Moderate Sell 0
Strong Sell 0
Current Average Recommendation (1.0=Strong Buy, 5.0=Strong Sell): 1.3
Last Weeks Average Recommendation: 1.4
Change In Average Recommendation: 0.1
Sieht doch echt gut aus...
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
41 | ||
38 | ||
34 | ||
28 | ||
24 | ||
20 | ||
18 | ||
16 | ||
13 | ||
10 |
Wertpapier | Beiträge | |
---|---|---|
10 | ||
9 | ||
9 | ||
9 | ||
8 | ||
8 | ||
7 | ||
7 | ||
7 | ||
6 |